Details how the factors that drove clinical use of high-dose chemotherapy with autologous bone marrow transplantation (HDC/ABMT)-patient demand, physician enthusiasm, media reporting, litigation, and administrative mandates-converged to propel the procedure forward despite a lack of proven clinical effectiveness. False Hope also analyzes the failure of the technology assessments and randomized clinical trials that evaluated the procedure and the ramifications of this flawed system on health care today. Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section addresses the significance of the story for our health care system.

Copies available from booksellers or the publisher. Published by Oxford University Press.

This report is part of the RAND Corporation commercial book series. Periodically, RAND Corporation researchers publish with commercial presses. These books are not available from RAND but can be requested directly from the publisher, except in cases where the rights have reverted to RAND and we have republished a new edition.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.